Summary
Piroxantrone, a synthetic intercalating agent, was studied in patients with advanced, measurable gastric adenocarcinoma who had not received prior chemotherapy. The starting piroxantrone dose was 150 mg/m2 given intravenously over 1 hour on day 1 and repeated every 21 days. Response and toxicity could be evaluated in 15 patients. No complete, partial, or minor responses were observed. Toxic effects included granulocytopenia, anemia, vomiting, nausea, anorexia, fatigue, stomatitis, alopecia, hyperbilirubinemia, and increased alkaline phosphatase levels. At the stated dose and schedule, piroxantrone does not possess significant activity against advanced gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Soh LT, Ajani JA: Gastric carcinoma. In: Pazdur R (ed.) Medical Oncology. A Comprehensive Review. PRR Inc., Huntington, New York, 1993, pp 165–174
Showalter HD, Johnson JL, Werbel LM, Leopold WR, Jackson RC, Elslager EF: 5-[(aminoalky)amino] substituted anthra[1,9-cd]pyrazol-6(2h)-ones as novel anti-cancer agents. Synthesis and biological evaluations. J Med Chem 27:253–255, 1984
Leopold WR, Nelson JM, Plowman J, Jackson RC: Anthrapyrazoles, a new class of intercalating agents against murine tumors. Cancer Res 45:5532–5539, 1985
Burchenal J, Pancoast T, Elslayer E: Anthrapyrazole and amasacrine analogues in mouse and human leukemia in vitro and in vivo. Proc Am Assoc Cancer Res 26:339, 1985 (abstract)
Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG: Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride (Oxantrazole). Cancer Res 50:3905–3909, 1990
Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990
Ajani JA, Welch SR, Raber MN: Comprehensive criteria for survival in therapy-induced toxicity. Cancer Invest 8:141–53, 1990
Zulupski MM, Benedetti J, Balcerzak SP, Hutchines LF, Belt RJ, Hantel A, Goodwin JW: Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study. Invest New Drugs 11:337–341, 1993
Jenkins TR, Tangen C, Macdonald JS, Weiss G, Chapman R, Hantel A: A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. Invest New Drugs 11:329–331, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pazdur, R., Bready, B., Scalzo, A.J. et al. Phase II trial of piroxantrone in metastatic gastric adenocarcinoma. Invest New Drugs 12, 263–265 (1994). https://doi.org/10.1007/BF00873970
Issue Date:
DOI: https://doi.org/10.1007/BF00873970